The Therapeutic Effects of Ceylon Cinnamon Supplementation and a Self-Efficacy Educational Program on Glycemic Control, Lipid Profiles, and Pain in Type 2 Diabetes Mellitus With Painful Diabetic Peripheral Neuropathy (Ceylon-EDU-RCT)
The Therapeutic Effects of Ceylon Cinnamon Supplementation and a Self-Efficacy Educational Program on Glycemic Control, Lipid Profiles, and Pain in Type 2 Diabetes Mellitus With Painful Diabetic Peripheral Neuropathy: A Randomized Controlled Trial
Studieoversigt
Status
Status
Betingelser
Betingelser
Intervention / Behandling
Intervention / Behandling
Detaljeret beskrivelse
Type 2 diabetes mellitus (T2DM) is a major global health challenge often complicated by diabetic peripheral neuropathy (DPN), which frequently manifests as painful diabetic peripheral neuropathy (PDPN) and severely compromises patients' quality of life. Conventional pharmacological treatments for PDPN often produce limited efficacy and adverse side effects, necessitating safe and effective complementary interventions.
This study is a prospective, three-group, parallel-arm, randomized controlled trial (RCT) designed to investigate the synergistic therapeutic impact of botanical supplementation and behavioral education. A total of 900 eligible adult participants diagnosed with T2DM and PDPN attending clinical healthcare centers will be enrolled and randomly allocated in a 1:1:1 ratio into one of three trial arms:
Control Group (Standard Care, n = 300): Participants receive routine diabetic medical care, standard counseling, and matching placebo capsules administered twice daily for 6 months, without structured educational interventions.
Cinnamon Supplementation Group (n = 300): Participants receive standard routine care alongside pure Ceylon cinnamon (Cinnamomum verum) extract capsules (500 mg orally twice daily with meals, total daily dose: 1,000 mg) for 6 months, combined with a double-blind placebo control for the educational component.
Combined Intervention Group (n = 300): Participants receive the identical daily regimen of 1,000 mg Ceylon cinnamon supplementation for 6 months, integrated with a structured, theory-driven Self-Efficacy-Based Educational Program grounded in Bandura's social cognitive theory. The educational program focuses on self-monitoring of blood glucose (SMBG), medication and supplement adherence, dietary modifications, foot care, and psychological coping strategies for chronic pain.
Primary and Secondary Endpoints:
Evaluations will be conducted at baseline and 6 months post-intervention. Primary outcomes include changes in glycated hemoglobin (HbA1c), fasting blood glucose (FBG), insulin resistance (HOMA-IR), and neuropathic pain severity assessed via the Numeric Rating Scale (NRS). Secondary outcomes include lipid profile biomarkers (Total Cholesterol, Triglycerides, LDL-C, and HDL-C), patient adherence, and safety/adverse event tracking. Statistical analyses will utilize repeated measures ANOVA and mixed-model frameworks to evaluate longitudinal and between-group differences.
Undersøgelsestype
Undersøgelsestype
Tilmelding (Anslået)
Tilmelding
Fase
Fase
- Ikke anvendelig
Kontakter og lokationer
Studiekontakt
Studiekontakt
- Navn: Dr. Jawad AHMAD ABU-SHENNAR, Asst.Prof.Dr
- Telefonnummer: +962779084560
- E-mail: JAWAD_0799@YAHOO.COM
Deltagelseskriterier
Berettigelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
- Voksen
- Ældre voksen
Tager imod sunde frivillige
Beskrivelse
Inclusion Criteria:
- Diagnosed with Type 2 Diabetes Mellitus (T2DM) for at least 6 months.
- Confirmed diagnosis of painful diabetic peripheral neuropathy (PDPN).
- Age between 18 and 65 years.
- Able to provide written informed consent and willing to comply with the study protocol, supplement intake, and educational sessions.
Exclusion Criteria:
- Type 1 diabetes mellitus or gestational diabetes.
- Severe renal or hepatic impairment.
- Known allergy, hypersensitivity, or contraindication to cinnamon or related botanical products.
- Pregnancy or lactation.
- Concurrent participation in another clinical trial or severe psychiatric/cognitive disorders that hinder study participation.
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Forebyggelse
- Tildeling: Randomiseret
- Interventionel model: Parallel tildeling
- Maskning: Enkelt
Antal våben
Våben og indgreb
Deltagergruppe / ArmDeltagergruppe / Arm |
Intervention / BehandlingIntervention / Behandling |
|---|---|
|
Aktiv komparator: Matching Placebo Group
Participants receive routine diabetes medical care and matching placebo capsules administered twice daily for 6 months.
|
Placebo capsules identical in appearance, color, and packaging to the cinnamon supplement, taken twice daily for 6 months
|
|
Eksperimentel: Ceylon Cinnamon Group
Participants receive routine diabetes medical care and pure Ceylon cinnamon (Cinnamomum verum) extract capsules (500 mg orally twice daily, total daily dose: 1,000 mg) for 6 months.
|
Placebo capsules identical in appearance, color, and packaging to the cinnamon supplement, taken twice daily for 6 months
Pure Ceylon cinnamon extract capsules (500 mg per capsule, taken twice daily, total dose 1,000 mg/day for 6 months).
|
|
Eksperimentel: Combined Intervention Group
Participants receive routine diabetes medical care, 1,000 mg/day Ceylon cinnamon supplementation for 6 months, and a structured Self-Efficacy-Based Educational Program grounded in Bandura's social cognitive theory.
|
Pure Ceylon cinnamon extract capsules (500 mg per capsule, taken twice daily, total dose 1,000 mg/day for 6 months).
A structured educational program grounded in Bandura's social cognitive theory aimed at enhancing self-efficacy and self-management skills evaluated using the Diabetes Self-Efficacy Scale (DSES)in participants with diabetes
|
Hvad måler undersøgelsen?
Primære resultatmål
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Change in Glycated Hemoglobin (HbA1c)
Tidsramme: Baseline and 6 months
|
Evaluated from venous blood samples to assess glycemic control over the preceding 2 to 3 months, expressed as a percentage (%).
Lower values indicate a better outcome (improved long-term glycemic control).
Normal reference ranges typically fall below 5.7%, with diabetes management targets generally aiming for levels below 7.0%
|
Baseline and 6 months
|
Sekundære resultatmål
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Change in Fasting Blood Glucose (FBG)
Tidsramme: Baseline, 3 months, and 6 months
|
Description: Evaluated from venous blood samples collected following an 8-hour overnight fast, measured in milligrams per deciliter (mg/dL).
Lower values indicate a better outcome (improved fasting glycemic status).
|
Baseline, 3 months, and 6 months
|
|
Change in Lipid Profile Parameters
Tidsramme: Baseline and 6 months
|
Evaluated from venous blood samples collected following an 8-hour overnight fast, measured in milligrams per deciliter (mg/dL). Directionality of improvement varies by component: Total Cholesterol: Lower values indicate a better outcome. Triglycerides: Lower values indicate a better outcome. Low-Density Lipoprotein Cholesterol (LDL-C): Lower values indicate a better outcome. High-Density Lipoprotein Cholesterol (HDL-C): Higher values indicate a better outcome. |
Baseline and 6 months
|
|
Change in Neuropathic Pain Intensity
Tidsramme: Baseline and 6 months (or Baseline, 3 months, and 6 months according to your protocol)
|
Evaluated using the Numerical Rating Scale (NRS).
Participants rate their average neuropathic pain intensity over the preceding 7 days.
Scores range from a minimum value of 0 (no pain) to a maximum value of 10 (worst possible pain).
Higher scores indicate a worse outcome (greater pain intensity).
Pain severity is categorized as mild (1-3), moderate (4-7), or severe (8-10).
|
Baseline and 6 months (or Baseline, 3 months, and 6 months according to your protocol)
|
|
Change in Diabetes Self-Efficacy Score
Tidsramme: Baseline and 6 months
|
Evaluated using the Diabetes Self-Efficacy Scale (DSES).
Item scores range from a minimum value of 1 (not at all confident) to a maximum value of 10 (totally confident), reported as an overall mean score (range 1-10).
Higher scores indicate
|
Baseline and 6 months
|
Samarbejdspartnere og efterforskere
Sponsor
Sponsor
Datoer for undersøgelser
Studer store datoer
Studiestart (Anslået)
Studiestart
Primær færdiggørelse (Anslået)
Primær færdiggørelse
Studieafslutning (Anslået)
Studieafslutning
Datoer for studieregistrering
Først indsendt
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Først opslået
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering sendt
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Nøgleord
Yderligere relevante MeSH-vilkår
- Smerte
- Neurologiske manifestationer
- Sygdomme i det endokrine system
- Sygdomme i nervesystemet
- Neuromuskulære sygdomme
- Metaboliske sygdomme
- Sygdomme i det perifere nervesystem
- Glukosemetabolismeforstyrrelser
- Diabetes mellitus
- Patologiske tilstande, tegn og symptomer
- Ernæringsmæssige og metaboliske sygdomme
- Tegn og symptomer
- Diabetes mellitus, type 2
- Neuralgi
Andre undersøgelses-id-numre
Andre undersøgelses-id-numre
- Educat vs. Ceyl-2026
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .